Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

COMPASS Pathways Plc (CMPS) — LONDON & NEW YORK, September 10, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuri

Source: Business Wire — read the full announcement there.

See our COMPASS Pathways company profile for background, links, and more COMPASS Pathways news.